TKG-002 / TKG Therapeutics - LARVOL DELTA

Selective tumor immune activation by novel nucleic acid drug (AACR 2026) - "The suppression of miR-21-overexpressing cancer growth by TKG-002 represents a potent therapeutic modality enabling selective tumor lysis through intracellular DNA self-assembly. The engineered TKG-002 induced autoimmunity toward targeted tumor lysis by forming long double-stranded DNA via miR-21. Further safety evaluation and condition optimization of TKG-002 are expected to establish it as an efficient cancer treatment modality."

IO biomarker • Oncology • CD4 • CD8 • MIR21